A new collaboration will see Californian biotech Kezar Life Sciences (Nasdaq: KZR) and China’s Everest Medicines (HKEX: 1952) working together on an immunoproteasome blocker, zetomipzomib.
The first-in-class therapy is believed to have broad therapeutic potential across multiple autoimmune diseases.
Kezar will receive an initial payment, plus development milestones, with a total deal value of about $130 million. Everest will also pay royalties on sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze